Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
2017 · New England Journal of Medicine · 738 citations
https://doi.org/10.1056/nejmoa1708538
A
Adam Cuker
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
377
Papers
17.3K
Citations
61
h-index
162
i10-index
Adam Cuker is an academic researcher from Hospital of the University of Pennsylvania. The author has contributed to research in topics: Venous Thromboembolism Diagnosis and Management & Platelet Disorders and Treatments & Heparin-Induced Thrombocytopenia and Thrombosis. The author has an h-index of 61, co-authored 321 publications.
ORCID: 0000-0002-3595-5697Papers by this author
worksAmerican Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia
2018 · Blood Advances · 684 citations
https://doi.org/10.1182/bloodadvances.2018024489
The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli
2020 · Scientific Reports · 247 citations
https://doi.org/10.1038/s41598-020-59526-x
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B
2024 · New England Journal of Medicine · 66 citations
https://doi.org/10.1056/nejmoa2302982
Evidence to Decision framework provides a structured “roadmap” for making GRADE guidelines recommendations
2018 · Journal of Clinical Epidemiology · 61 citations
https://doi.org/10.1016/j.jclinepi.2018.09.007
A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study
2022 · EClinicalMedicine · 31 citations
https://doi.org/10.1016/j.eclinm.2022.101745
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat